222 related articles for article (PubMed ID: 28085753)
1. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?
Thota R; Maitra A; Berlin JD
Pancreas; 2017 Feb; 46(2):143-150. PubMed ID: 28085753
[TBL] [Abstract][Full Text] [Related]
2. [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review].
Azria D; Seblain-El-Guerche C; Girard N; Hennequin C; Huguet F
Bull Cancer; 2008 Nov; 95(11):1116-30. PubMed ID: 19036684
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002)].
Fung MC; Takayama S; Ishiguro H; Sakata T; Adachi S; Morizane T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1101-11. PubMed ID: 12938264
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
Rubinson DA; Wolpin BM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
[TBL] [Abstract][Full Text] [Related]
5. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
[TBL] [Abstract][Full Text] [Related]
6. A review of systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
[TBL] [Abstract][Full Text] [Related]
7. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
8. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer.
Sgouros J; Maraveyas A
Acta Oncol; 2008; 47(3):337-46. PubMed ID: 17957501
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab: still an option in the treatment of pancreatic cancer?
Faloppi L; Andrikou K; Cascinu S
Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
[No Abstract] [Full Text] [Related]
11. Second-line therapy in pancreatic cancer.
Skoura E; Syrigos KN; Saif MW
JOP; 2013 Mar; 14(2):133-4. PubMed ID: 23474554
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
Aprile G; Negri FV; Giuliani F; De Carlo E; Melisi D; Simionato F; Silvestris N; Brunetti O; Leone F; Marino D; Santini D; Dell'Aquila E; Zeppola T; Puzzoni M; Scartozzi M
Crit Rev Oncol Hematol; 2017 Jul; 115():1-12. PubMed ID: 28602164
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF; Li GJ; Zhao H
J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
[TBL] [Abstract][Full Text] [Related]
14. Second line treatment options for pancreatic cancer.
Passero FC; Saif MW
Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
16. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.
Rahib L; Fleshman JM; Matrisian LM; Berlin JD
JAMA Oncol; 2016 Sep; 2(9):1209-16. PubMed ID: 27270617
[TBL] [Abstract][Full Text] [Related]
18. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan in the management of patients with pancreatic cancer.
Green MR; Harper M; Safa A; Sherman CA; Mushtaq CM; Bahadori H; Brescia FJ; Rocha Lima CM
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):31-3. PubMed ID: 11200146
[TBL] [Abstract][Full Text] [Related]
20. The winning formulation: the development of paclitaxel in pancreatic cancer.
Ma WW; Hidalgo M
Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
